Product nameVandetanib, VEGFR2 tyrosine kinase inhibitor
DescriptionOrally available, potent VEGFR2 tyrosine kinase inhibitor
- CH 331
Orally available, potent VEGFR2 tyrosine kinase inhibitor (KDR IC50 = 40 nM). Also inhibits fms-like tyrosine kinase 4 (VEGFR3, IC50 = 110 nM) and epidermal growth factor receptor (EGFR/HER1, IC50 = 500 nM) but shows selectivity against a panel of other tyrosine and serine-threonine kinases. Displays anti-angiogenesis activity.
Chemical nameN-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy] quinazolin-4-amine
Storage instructionsShipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
Solubility overviewSoluble in DMSO to 50 mM and in ethanol to 10 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
This product has been referenced in:
- Morabito A et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14:378-90 (2009). Read more (PubMed: 19349511) »
- Herbst RS et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-49 (2007). Read more (PubMed: 17243944) »
- Ciardiello F et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-56 (2003). Read more (PubMed: 12684431) »
- Wedge SR et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-55 (2002). Read more (PubMed: 12183421) »